Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anebulo Pharmaceuticals Inc (ANEB)

Anebulo Pharmaceuticals Inc (ANEB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 94,085
  • Shares Outstanding, K 41,085
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,480 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta -0.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.05
  • Growth Rate Est. (year over year) +1,998,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.15 +0.93%
on 12/11/25
2.49 -12.85%
on 11/25/25
-0.11 (-4.82%)
since 11/14/25
3-Month
2.15 +0.93%
on 12/11/25
2.85 -23.86%
on 10/20/25
-0.29 (-11.79%)
since 09/15/25
52-Week
0.80 +171.22%
on 12/20/24
3.42 -36.55%
on 07/23/25
+0.77 (+55.00%)
since 12/13/24

Most Recent Stories

More News
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company”...

ANEB : 2.17 (-5.24%)
Anebulo Pharmaceuticals’ Bold Move: Potential Risks of Going Private with Reverse Stock Split

Anebulo Pharmaceuticals, Inc. (ANEB) has disclosed a new risk, in the Share Price & Shareholder Rights category.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful...

ANEB : 2.17 (-5.24%)
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company”...

ANEB : 2.17 (-5.24%)
Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the “Company”...

ANEB : 2.17 (-5.24%)
Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the “Company”...

ANEB : 2.17 (-5.24%)
Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company”...

ANEB : 2.17 (-5.24%)
Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

/PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from...

ANEB : 2.17 (-5.24%)
Ligand Reports First Quarter 2023 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management...

TVTX : 34.76 (-0.20%)
VKTX : 36.15 (-2.51%)
LGND : 192.88 (+1.76%)
ANEB : 2.17 (-5.24%)
NVS : 135.19 (+1.98%)
NOVN : 0.0941 (-24.84%)
Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

/PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (the "Company" or "Anebulo"), a clinical-stage biopharmaceutical company developing novel...

ANEB : 2.17 (-5.24%)
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company”...

ANEB : 2.17 (-5.24%)

Business Summary

Anebulo Pharmaceuticals Inc. is a clinical-stage biotechnology company. It involved in developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The company's product candidate includes ANEB-001. Anebulo Pharmaceuticals Inc. is based in Texas, United States.

See More

Key Turning Points

3rd Resistance Point 2.45
2nd Resistance Point 2.37
1st Resistance Point 2.33
Last Price 2.17
1st Support Level 2.21
2nd Support Level 2.13
3rd Support Level 2.08

See More

52-Week High 3.42
Fibonacci 61.8% 2.42
Last Price 2.17
Fibonacci 50% 2.11
Fibonacci 38.2% 1.80
52-Week Low 0.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar